Chuan Yan

Chuan Yan

Auto-generated profile, based on publicly available information

Chuan Yan

Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2020 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
MFMaurizio Fazio
Maurizio Fazio
JAJulien Ablain
Julien Ablain
YCYan Chuan
Yan Chuan
DLDavid M. Langenau
David M. Langenau
LZLeonard I. Zon
Leonard I. Zon

18 August 2022 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
YWYun Wei
Yun Wei
QQQian Qin
Qian Qin
CYChuan Yan
Chuan Yan
MHMadeline N. Hayes
Madeline N. Hayes
SGSara P. Garcia
Sara P. Garcia
DLDavid M. Langenau
David M. Langenau

20 August 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CYChuan Yan
Chuan Yan
QYQiqi Yang
Qiqi Yang
SZSongfa Zhang
Songfa Zhang
DMDavid G. Millar
David G. Millar
EAEric J. Alpert
Eric J. Alpert
DLDavid M. Langenau
David M. Langenau
T cell immunotherapies have revolutionized treatment for a subset of cancers. Yet, a major hurdle has been the lack of facile and predicative preclinical animal models that permit dynamic visualization of T cell immune responses at single-cell resolution in vivo. Here, optically clear immunocompromised zebrafish were engrafted with fluorescent-labeled human cancers along with chimeric antigen receptor T (CAR T) cells, bispecific T cell engagers (BiTEs), and antibody peptide epitope conjugates (APECs), allowing real-time single-cell visualization of T cell–based immunotherapies in vivo. This work uncovered important differences in the kinetics of T cell infiltration, tumor cell engagement, and killing between these immunotherapies and established early endpoint analysis to predict therapy responses. We also established EGFR-targeted immunotherapies as a powerful approach to kill rhabdomyosarcoma muscle cancers, providing strong preclinical rationale for assessing a wider array of T cell immunotherapies in this disease.

21 August 2020 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
CYChuan Yan
Chuan Yan
DDDaniel Do
Daniel Do
QYQiqi Yang
Qiqi Yang
DBDalton C. Brunson
Dalton C. Brunson
JRJohn F. Rawls
John F. Rawls
DLDavid M. Langenau
David M. Langenau

30 June 2020 in Leukemia
Verified
Journal Article
Closed access
PDF file
EGE. G. Garcia
E. G. Garcia
AVA. Veloso
A. Veloso
MOM. L. Oliveira
M. L. Oliveira
JAJ. R. Allen
J. R. Allen
SLS. Loontiens
S. Loontiens
DLD. M. Langenau
D. M. Langenau

1 November 2020 in Animal Feed Science and Technology
Verified
Journal Article
Closed access
DMDaolin Mou
Daolin Mou
SLShuang Li
Shuang Li
CYChuan Yan
Chuan Yan
QZQianqian Zhang
Qianqian Zhang
JLJing Li
Jing Li
DWDe Wu
De Wu